Yüklüyor......
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously reported that STK11/LKB1 (KL) or TP53 (KP) co-mutations define distinct subgroups of KRAS-mutant LUAC. Here, we examine the efficacy of PD-1 inhibitors in these subgroups. Objective response rates to PD-1 blockade...
Kaydedildi:
| Yayımlandı: | Cancer Discov |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2018
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6030433/ https://ncbi.nlm.nih.gov/pubmed/29773717 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-18-0099 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|